DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty.

Author(s): Fokter SK, Komadina R, Repse-Fokter A, Yerby SA, Kocijancic A, Marc J

Affiliation(s): Department of Orthopaedic Surgery and Sports Trauma, Celje General Hospital, Oblakova 5, 3000, Celje, Slovenia. samo.fokter@guest.arnes.si

Publication date & source: 2005-12, Int Orthop., 29(6):362-7. Epub 2005 Sep 29.

Publication type: Randomized Controlled Trial

Periprosthetic bone loss after arthroplasty may threaten prosthesis survival. The current study investigated the effect of etidronate therapy on periprosthetic, contralateral hip, and spine bone mineral density (BMD) in a one-year, prospective, randomized, double-blind study on 46 patients after cemented hip arthroplasty. BMD was measured with dual-energy X-ray absorptiometry (DXA). There were no significant differences between mean BMD measurements of the etidronate and placebo groups, with the exception of the mean percent change in the spine at six months and 12 months and in Gruen zone 3 at six months; in all three cases, the etidronate group had significantly greater mean values. These findings suggest that cyclic etidronate therapy has no significant effect in suppressing periprosthetic bone loss following cemented hip arthroplasty.

Page last updated: 2006-11-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017